

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

January 11, 2017

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for October 19, 2016 meeting
- IV. Secretary's report
- V. Old Business
 - A. Amerigroup's response to Miralax® in step therapy for OIC
 - B. Naloxone as physician-administered drug from June 2016: indications/diagnosis
 - C. Smoking cessation therapy update: Dr. Jill Williams
- VI. New Business
 - A. Proposed educational newsletter: "Using Naloxone to Prevent Drug Overdose Deaths"
 - B. Protocol review:
 1. Smoking cessation products
 2. Addiction treatment drugs
- VII. Informational Highlights/Reports
 1. Molina/NJ HMO 3rd Quarter 2016 Prior Authorization Report
 2. Summary of DURB Action Items
 3. (a) DHS and DHSS Programs Top Drugs Report (by amount paid and by category)
(b) Physician-administered drugs by amount paid/category
 4. Medication information:
 - (a) FDA Approves Bonjesta for Pregnancy-Related Nausea and Vomiting
 - (b) Could Common Heartburn Drugs Up Stroke Risk?
 - (c) Direct-Acting Antivirals for Hep C might Worsen Liver Cancer
 - (d) FDA Announces Stern New Warning Labels for Testosterone Treatments